On January 9, 2026, David Kang of B. Riley Financial issued a new price target of $18 for AXTI, representing a potential downside of approximately 30% from current trading levels. Kang cited valuation concerns and the potential for continued export-control challenges in his assessment. This marks the second downward revision of the year and underscores growing skepticism among sell-side analysts about near-term upside for the stock.

AXT revised its fourth-quarter revenue forecast to a range of $22.5 million to $23.5 million, down from prior guidance of $26 million to $28 million. The adjustment reflects a slowdown in export permits for indium phosphide substrates issued by China’s Ministry of Commerce, which constrained shipments during the quarter. Management now anticipates that permit volumes will normalize in early 2026 as regulatory processing speeds recover.

Despite the guidance revision, AXTI shares rallied 7.13% on the day of the announcement, trading between $22.90 and $25.97. The stock’s 52-week range stands at $1.13 to $25.98, and the company’s market capitalization is approximately $1.16 billion. Daily trading volume has averaged over 11 million shares in recent sessions, signaling robust institutional and retail interest despite heightened volatility.

Investors are now focused on AXTI’s fiscal Q4 earnings release scheduled for February 19, 2026. Consensus estimates anticipate a quarterly revenue decline of 6% year-over-year and a widened net loss margin, driven by lower substrate sales and ongoing R&D investments. Management commentary on permit backlog resolution and the ramp of new gallium-arsenide capacity will be key factors for the stock’s next directional move.